Sherman Knight (jurykenya63)

s high (7/48; 15%). CONCLUSION Our hypothesis was confirmed since the outcomes were satisfactory, but mortality and morbidity were high. Performing hTKA remains an option in the post-fracture context, although surgeons must carefully consider the indications. LEVEL OF EVIDENCE IV, retrospective study. BACKGROUND One-stage bilateral hip replacement has the advantage of involving a single anesthesia, single hospital admission and single rehabilitation program. The theoretic drawback is increased surgical risk. Few French series have been reported, and none with comparison versus unilateral arthroplasty. We therefore conducted a comparative case-control study between 1-stage bilateral (1B-THA) and unilateral total hip arthroplasty (U-THA), assessing (1) morbidity/mortality, (2) survival, and (3) functional scores and forgotten hip rates. HYPOTHESIS In a selected ASA 1 or 2 population, 1B-THA shows complications rates and implant survival comparable to U-THA. Lonafarnib MATERIAL AND METHOD Between 2004 and 2018, 327 patients were included 109 with 1B-THA, 218 with U-THA. One 1B-THA patient was matched to 2 U-THA patients on age, gender, diagnosis, ASA score 1 or 2, and anterior or posterior approach. Minimum follow-up was 12 months. Complications were collected for all patients in both groups. Early (≤90 days) or late (>cations and implant survival were unaffected, but the 1-stage bilateral procedure allowed better control of limb-length and provided a higher rate of forgotten hip. LEVEL OF EVIDENCE III, matched case-control study. OBJECTIVES To describe the increasing complexity and scope of clinical trials research, convergent research, and the clinical nurse roles and responsibilities to ensure safe patient care and study data integrity. DATA SOURCES Textbooks, journal publications, federal regulations, US Food and Drug Administration documents, clinical practice guidelines. CONCLUSION The immune system, genetics, and molecular pathology are not new in the context of oncology treatments. The reliability and clinical validation of in vitro diagnostic medical devices is, however, becoming increasingly more important in the development of marker driven targeted therapies, immunotherapy, and adoptive T-cell transfer. Protecting patients and preserving the integrity of clinical trials is of utmost importance. IMPLICATIONS FOR NURSING PRACTICE The role and scope of oncology and research nurses will intersect and shift as clinical care continues to involve high-acuity patients who participate in complex in vitro diagnostic and therapeutics clinical trials. The expertise of oncology nurses may vary in skills and knowledge domain; however, all scopes of practice are underpinned by the nursing code of ethics to ensure accountability for all aspects of patient care. OBJECTIVE To explore the various types and phases of clinical trials, the regulatory oversight, drug approval process, and implications of clinical trials for the oncology nurse. DATA SOURCES Peer-reviewed journal articles, internet, book chapters, white papers. CONCLUSION Oncology nurses' interactions with patients entered on clinical trial and communication with the clinical research team is crucial to the successful conduct of clinical trials. The oncology nurse must work in concert with the clinical research team to protect patient safety and to produce accurate information for protocol requirements that will be used to evaluate whether a drug becomes approved or not by the US Food and Drug Administration. IMPLICATIONS FOR NURSING PRACTICE Oncology nurses play a central role to the successful outcome of clinical research studies. Nurses must work in close collaboration with the clinical research teams for the successful completion and adherence of the clinical trial and to maintain the safety of the patient enrolled into clinical trial. OBJECTIVES This article will provide an overview of the purpose, structure, and function of an investigational pharmacy in oncology